- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Bone marrow derived macrophages.
Displaying page 1 of 1.
EudraCT Number: 2017-001853-15 | Sponsor Protocol Number: NL61830 | Start Date*: 2018-07-11 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells. | ||
Medical condition: Pulmonary emphysema | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003317-33 | Sponsor Protocol Number: CyPep-1 | Start Date*: 2019-12-31 |
Sponsor Name:Cytovation ASA | ||
Full Title: A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and ... | ||
Medical condition: Histologically or cytologically confirmed locally advanced (unresectable) or metastatic tumors (solid tumors or lymphoma) with an accessible tumor lesion for intratumoral injection of CyPep-1 that ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) FR (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001491-35 | Sponsor Protocol Number: CB103-C-101 | Start Date*: 2017-08-11 | ||||||||||||||||
Sponsor Name:Cellestia Biotech AG | ||||||||||||||||||
Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu... | ||||||||||||||||||
Medical condition: advanced or metastatic solid tumours and haematological malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
